Differential effects of estrogen and prolactin on autoimmune disease in the NZB/NZW F1 mouse model of systemic lupus erythematosus

Abstract

Estrogen and prolactin have been shown to modulate autoimmunity in the NZB/NZW F1 (B/W) mouse model of systemic lupus erythematosus (SLE). However, estrogen stimulates prolactin secretion. The goal of this study was to examine differential effects of estrogen and prolactin in the female B/W mouse model of SLE. B/W females were manipulated to create combinations of low and high concentrations of serum estrogen and prolactin. Hyperprolactinemic mice with either low or high serum estrogen levels had accelerated development of albuminuria at 24 and 32 weeks of age compared to normal and hypoprolatinemic mice. High estrogen/high prolactin mice also had a higher percentage of anti-DNA antibodies compared to mice in the low estrogen/low prolactin and the high estrogen/low prolactin groups. IgG levels were not significantly different between groups. Mean survival was shortest in the high estrogen/high prolactin group (34 1.0 weeks) and longest in the high estrogen/low prolactin group (42 1.2 weeks; P < 0.05). High levels of serum estrogen were associated with depressed in vitro lymphoproliferation and IL-2 production. This study suggests that high prolactin levels in either high or low serum estrogen states are associated with accelerated autoimmunity in the B/W mouse. This study further demonstrates that high estrogen levels do not accelerate murine SLE when the prolactin-stimulating property of estrogen is suppressed by bromocriptine. Further investigation of hormonal interactions in autoimmunity will provide a better understanding of hormonal immunoregulation and, perhaps, lead to improved clinical application of hormonal immunomodulation.

Keywords

lupus estrogen prolactin hormone mice

Get full access to this article

View all access options for this article.

References

Rothfield N . Clinical features of systemic lupus erythematosus. In: Kelley WN , Harris ED ,. Ruddy S , Sledge CB (eds.) Textbook of Rheumatology WB Suanders Co.: Philadelphia , 1985; 1069–1089.

Reeves WH , Lahita RB . Clinical presentation of systemic lupus erythematosus in the adult. In: Lahita RG (ed). Systemic Lupus Erythematosus Churchill Livingston: New York . 1992; 369–396.

Inman RD . Immunologic sex differences and the female predominance in systemic lupus erythematosus . Arthritis Rheum 1978; 21: 849–852 .

Theofilopoulos AN . Sex and Sex Hormones. In: Lahita RG (ed). Systemic Lupus Erythematosus Churchill Livingston: New York . 1992; 167–169.

Masi AT , Kaslow RA . Sex effects in systemic lupus erythematosus . Arthritis Rheum 1978; 21: 480–483 .

Rose E , Pillsbury DM . Lupus erythematosus (erythematodes) and ovarian function: Observations on a possible relationship with a report of six cases . Ann Intern Med 1944; 21: 1022–1034 .

Jungers P et al. Influence of oral contraceptive therapy on activity of systemic lupus erythematosus . Arthritis Rheum 1982; 25: 618–623 .

Petri M , Howard D , Repke J . Frequency of lupus flare in pregnancy. The Hopkins Lupus Pregnancy Center experience . Arthritis Rheum 1991; 34: 1538–1545 .

Parke AL . Pregnancy and SLE. In: Lahita RG (ed). Systemic Lupus Erythematosus Churchill Livingston: New York , 1992; 543–560.

10.

Lahita RB et al. Increased 16 alpha-hydroxylation of estradiol in systemic lupus erythematosus . J Clin Endocrinol Metab 1981; 53: 174–178 .

11.

Lahita RG , Kunkel HG , Barlow HL . Increased oxidation of testosterone in systemic lupus erythematosus . Arthritis Rheum 1983; 26: 1517–1521 .

12.

Lahita RG et al. Low plasma androgens in women with systemic lupus erythematosus . Arthritis Rheum 1979; 20: 1195–1198 .

13.

McMurray RW et al. Lonstanding hyperprolactinemia associated with systemic lupus erythematosus: Possible hormonal stimulation of an autoimmune disease . J Rheum 194; 21: 843–850 .

14.

Jara LJ et al. Hyperprolactinemia in systemic lupus erythematosus: association with disease activity . Am J Med Sci 1992; 303: 222–226 .

15.

Theofilopoulos AN . Murine models of lupus. Lahita RG (ed). Systemic Lupus Erythematosus 2nd edition, Churchill Livingston: New York , 1992; 121–194.

16.

Roubinian J , Talal N , Siiteri PK , Sadakian JA . Sex hormone modulation of autoimmunity in NZB/NZW mice . Arthritis Rheum 1979; 22: 1162–1169 .

17.

Steinberg AD et al. Approach to the study of the role of sex hormones in autoimmunity . Arthritis Rheum 1979; 22: 1170–1176 .

18.

McMurrary R et al. Prolactin influences autoimmune disease activity in the female B/W mouse . J Immunol 1991; 147: 2780–3787 .

19.

Frantz AG . Prolactin . N Eng J Med 1978; 298: 201–207 .

20.

Reichlin S . Neuroendocrinology. In: Wilson JD , Foster DW (eds). Williams' Textbook of Endocrinology. WB Saunders: Philadelphia , 1992; 203: 173–175.

21.

Chen CL , Meites J . Effects of estrogen and progesterone on serum and pituitary prolactin levels in ovariectomized rats . Endocrinol 1970; 86: 503–508 .

22.

Nogami H . Fine structural heterogeneity and morphologic changes in rat pituitary prolactin cells after estrogen and testosterone treatment . Cell Tissue Res 1984; 237: 195–199 .

23.

Carr BR . Disorders of the ovary and female reproductive tract. In: Wilson JD , Foster DW (eds). Williams' Textbook of Endocrinology. WB Saunders: Philadelphia , 1992; 733–798.

24.

Carlsten H , Tarowski A , Homdahl R , Nilsson LA . Oestrogen is a potent disease accelerator in SLE-prone MRL/lpr/lpr mice . Clin Exp Immunol 1990; 80: 467–473 .

25.

Holmdahl R , Carlsten H , Jansson L , Larsson P . Oestrogen is a potent immunomodulator murine experimental rheumatoid disease . Brit J Rheumatol 1989; 28 (Suppl I): 54–58 .

26.

Carlsten H , Holmdahl R , Tarkowski A , Nilsson LA . Oestradiol suppression of delayed type hypersensitivity in autoimmune (NZB/NZW) F1 mice is a trait inherited from the healthy NZW parental strain . Immunol 1989; 67: 205–209 .

27.

Carlsten H , Nilsson N , Jonsson R , Tarkowski A . Differential effects of oestrogen in murine lupus: acceleration of glomerulonephritis and amelioration of T cell mediated lesions . J Autoimmunity 1991; 4: 845–856 .

28.

Adler RA . The anterior pituitary-grafted rat: A valid model of chronic hyperprolactinemia . Endocr Rev 1986; 7: 320–313 .

29.

Mann MA , Michael SD , Svare B . Ergot drugs suppress plasma levels of prolactin (PRL) but not growth hormone (GH), luteinizing hormone (LH) or corticosterone (CORT) in parturient mice . Pharmacol Biochem Behavior 1982; 17: 837–840 .

30.

Zhou T et al. Origin of CD4-CD8-B220/ T cells in MRL-lpr/lpr mice. Clues from a T cell receptor beta transgenic mouse . J Immunol 1993; 150: 3651–3659 .

31.

Abbas AK , Uarioste S , Collins TL , Bloom WH . Heterogeneity of helper/inducer T lymphocytes IV. Stimulation of resting and activated B cells by Th1 and Th2 clones . J Immunol 1990; 144: 2031–2037 .

32.

Chi HJ , Shin SH . The effect of exposure to ether on prolactin secretion and the half-life of endogenous prolactin in normal and castrated male rats . Neuroendocrinology 1978; 26: 193–201 .

33.

Fox HS , Bond BL , Parslo TG . Estrogen regulates the IFN-gamma promoter . J Immunol 1991; 146: 4362–4357 .

34.

Sthoeger ZM , Chiorazzi N , Lahita RG . Regulation of the immune response by sex hormones. I. In vitro effects of estradiol and testosterone on pokeweed mitogen induced human B-cell differentiation . J Immunol 1998; 141: 91–98 .

35.

Ahmed SA , Dauphinee MH , Talal N . Effect of short-term administration of sex hormones on normal and autoimmune mice . J Immunol 1984; 134: 204–210 .

36.

Smithson G , Medicne K , Ponting I , Kincade PW . Estrogen suppresses stromal cell-dependent lymphopoiesis in culture . J Immunol 1995; 155: 3409–3417 .

37.

Schwarz LA , Stevens AM , Hrachovy JA , Yu-Lee L . Interferon regulatory factor-I is inducible by prolactin, interleukin-2, and concanavalin A in T cells . Mol Cell Endocrinol 1992; 86: 103–110 .

38.

Yu-Lee LY , Stevens AM , Hrachovy JA , Schwartz LA . Prolactinmediated regulation of gene transcription in lymphocytes . Ann NY Acad Sci 1990; 594: 146–155 .

39.

Cross RJ , Campbell JL , Roszman TL . Potentiation of antibody responsiveness after the transplantation of a syngeneic pituitary gland . J Neuroimmunol 1989; 25: 29–35 .

40.

Piccinni MP , Giudizi MG , Biagiotti R , Beloni L . Progesterone favors the development of human T helper cells producing Th2-Type cytokines and promotes both IL-4 production and membrane CD30 expression in established Th1 cell clones . J Immunol 1995; 155: 128–133 .

41.

Walker SE , McMurray RW , Besch-Williford CL , Keisler D . Premature death with bladder outlet obstruction and hyperprolactinemia in the New Zealand Black 6 New Zealand White mice treated with ethinyl estradiol and 17 beta-estradiol . Arthritis Rheum 1992; 35: 1387–1392 .

42.

Morikawa K , Oseko F , Moreikawa S . Immunosuppressive activity of bromocriptine on human T lymphocyte function in vitro . Clin Exp Immunol 1994; 95: 514–518 .

43.

Morikawa K , Oseko F , Morikawa S . Immunosuppressive property of bromocriptine on human B lymphocyte funciton in vitro . Clin Exp Immuno 1993; 93: 200–205 .

44.

Power RF , Lydon JP , Conneely BW , O'Malley BW . Dopamine activation of an orphan steroid receptor superfamily . Science 1991; 252: 1546–1548 .

45.

E Nagy et al. Immunomodulation by bromocriptine . Immunopharmacology 1983; 6: 231–243 .

46.

Bernton EW , Metzler MS , Holaday JW . Suppression of macrophage activation and T lymphocyte function in hypoprolactinemic mice . Science 1988; 239: 401–404 .

47.

Thorner MO , Vance ML , Horvath E , Kovacs K . The Anterior Pituitary. In: Wilson JD , Foster DW (eds). Williams' Textbook of Endocrinology. WB Saunders: Philadelphia , 1992; 226–228.

48.

Jacobsen JD , Nisula BC , Steinberg AD . Modulation of the expression of murine lupus by gonadotropin-releasing hormone analogs . Endocrinol 1994; 134: 2516–2523 .

49.

Cleavenger CV , Russell DH , Appasamy PM , Prystowsky MB . Regulation of interleukin-2 driven T-lymphocyte proliferation by prolactin . Proc Natl Acad Sci USA 1990; 87: 6460–6464 .

50.

McMurray RW , Weidensaul D , Allen SH , Walker SE . Efficacy of bromocriptine in an open label therapeutic trial for systemic lupus erythematosus . J Rheumatology 1995; 23: 1576–1590 .